A Phase 2 study of hMaxi-K as (URO-902) a treatment for OAB patients who have not responded to other pharmacological therapies
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Maxi-K gene therapy (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 13 Aug 2019 According to an Urovant Sciences media release, protocol of this trial has been finalized OAB and expect to start patient enrollment by the end of fourth quarter 2019.
- 13 Jun 2019 According to an Urovant Sciences media release, company gained general alignment with the FDA on the proposed protocol for this trial.
- 10 Sep 2018 New trial record